ElizabethGarnerMD

Obstetrics & Gynecology • Montclair, NJ

Gynecologic Oncology

Chief Scientific Officer, Ferring Pharmaceuticals US

Join to view full profile

Dr. Garner is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Garner's full profile

Already have an account?

Office
19 Undercliff Dr
Montclair, NJ 07042
Phone+1 267-218-2379

Education & Training

Harvard Medical SchoolClass of 1994
Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Obstetrics and Gynecology
Brigham and Women’s HospitalFellowship, Gynecologic Oncology

Certifications & Licensure

PA State Medical License 2016 - 2024

Publications & Presentations

PubMed

5 citations
Treatment of symptomatic uterine adenomyosis with linzagolix, an oral gonadotrophin-releasing hormone antagonist: a pilot study.
Jacques Donnez, Olivier Donnez, Michel Brethous, Elke Bestel, Elizabeth I.O. Garner
Reproductive Biomedicine Online. 2021-10-03
11 citations
Efficacy, safety, and tolerability of a levonorgestrel/ethinyl estradiol transdermal delivery system: Phase 3 clinical trial results.
Anita L. Nelson, Andrew M. Kaunitz, Robin Kroll, James A. Simon, Alfred N. Poindexter
Contraception. 2021-03-01
45 citations
C Terminus of Clostridium perfringens Enterotoxin Downregulates CLDN4 and Sensitizes Ovarian Cancer Cells to Taxol and Carboplatin
Zhijian Gao, Xiaoyin Xu, Bruce A. McClane, Qing Zeng, Babak Litkouhi
Clinical Cancer Research. 2011-03-01

Other

Gestational trophoblastic neoplasia: Staging and treatment
Garner EI
http://www.uptodate.com/contents/gestational-trophoblastic-neoplasia-staging-and-treatment
UpToDate, Wolters Kluwer Health - 2013-02-26

Press Mentions

Retrospective Analysis of Data Evaluating Safety and Efficacy of REBYOTA™ (Fecal Microbiota, Live – Jslm) in a Real-World Patient Population with Comorbidities and Risk Factors Published in Open Forum Infectious DiseasesMay 3rd, 2023
Birth Control Fail: Why American Women Can’t Have Better Contraceptives in 2023April 5th, 2023
Appendicitis More Often Missed in Patients Who Are BlackFebruary 15th, 2023
Join now to see all